August 25, 2021
“Enovix (ENVX)… Are other analysts in agreement? They are. Only Buy ratings, 3 to be exact, have been issued in the last three months. Therefore, the message is clear: ENVX is a Strong Buy. Given the $29.67 average price target, shares… Continue Reading…
June 2, 2021
“Aeva Technologies (AEVA)… Rusch rates this stock as Outperform (i.e., a Buy), and his $20 price target implies it has room for 104% growth in the next 12 months… Wall Street generally is even more bullish here than Rusch is. The… Continue Reading…
October 28, 2020
“Chromadex (CDXC)… It’s not often that the analysts all agree on a stock, so when it does happen, take note. CDXC’s Strong Buy consensus rating is based on a unanimous 3 Buys. The stock’s $7.67 average price target suggests a… Continue Reading…
October 13, 2020
“Outlook Therapeutics (OTLK)… Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, OLTK has a Strong Buy consensus rating. With the average price target clocking… Continue Reading…
September 30, 2020
“Brickell Biotech (BBI)… Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been published in the last three months. As a result, BBI gets a Moderate Buy consensus rating. The $5 average price target is identical… Continue Reading…
September 16, 2020
“MediWound Ltd. (MDWD)… To this end, DeGeeter rates MDWD an Outperform along with a $7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards… UroGen Pharma (URGN)… To this end, Gershell… Continue Reading…
September 2, 2020
“Baudax Bio (BXRX) First up we have Baudax Bio, which is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings. With shares changing hands for $2.80, Oppenheimer believes that the share price presents an attractive… Continue Reading…
Recent Comments